摘要
糖化血红蛋白(HbA1c)作为被英国前瞻性糖尿病研究(UKPDS)、美国糖尿病控制和并发症试验(DCCT)两大流行病学调查结果证实的与糖尿病及其并发症密切相关的重要标志物,在临床上得到了越来越广泛的应用。但是,HbA1c实验室检测技术的多样性导致其检测结果差异较大,无法满足临床诊治的需求。随着国际临床化学与医学实验室联盟(IFCC)和美国临床化学协会(AACC)HbA1c标准化工作的开展,实验室HbA1c的检测质量得到了显著提升。2010年起HbA1c先后被美国糖尿病协会(ADA)、国际糖尿病联盟(IDF)、世界卫生组织(WHO)等组织列入糖尿病诊断标准。在我国,HbA1c临床应用、检测质量管理和标准化工作启动相对较晚,但工作进展的速度和成绩也是有目共睹的。虽然暂时未被列入中国糖尿病诊断指南中,相信只要团结协作,必将开创出我国自己的HbA1c标准化之路,更好地为临床医生和糖尿病患者服务。
Hemoglobin A1c（HbA1c） is confirmed by the 2 epidemiological surveys,the UK Prospective Diabetes Study（ UKPDS） and the Diabetes Control and Complications Trial Research（ DCCT）,as an important marker which is closely related to diabetes and its complications. Hb A1 chas been used more and more widely in clinical laboratories.Due to the diversity of Hb A1 cdetection technologies,there is large difference among results,and thus it is unable to meet the demand of clinical diagnosis and treatment. Along with the International Federation of Clinical Chemistry and Laboratory Medicine（ IFCC） and American Association for Clinical Chemistry（ AACC） to carry out the Hb A1 c standardization,testing quality in laboratories has been significantly improved. Since 2010,Hb A1 chas been included in the diagnostic criteria for diabetes by American Diabetes Association（ ADA）,the International Diabetes Federation（IDF） and World Health Organization（WHO）. In China,Hb A1 cdetection begins relatively late in clinical application,quality management and standardization,but the rate of progress of work and performance are very obvious. Although Hb A1 chas temporarily not been included in the Chinese diabetes diagnosis guide,we believe that as long as we keep the unity and cooperation,we will create standardization in our own way and serve the clinicians and patients with diabetes mellitus better.
出处
《检验医学》
CAS
2015年第6期547-553,共7页
Laboratory Medicine
基金
上海市卫生和计划生育委员会资助项目(2013ZYJB0010)
关键词
糖化血红蛋白
质量管理
标准化
Hemoglobin A1c
Quality management
Standardization
